Repligen Exits Third Quarter Armed With a $500 Million War Chest [The Motley Fool]
Repligen Corporation (RGEN)
Last repligen corporation earnings: 2/20 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
repligen.com/investors
Company Research
Source: The Motley Fool
Repligen Exits Third Quarter Armed With a $500 Million War Chest After an eventful first half of the year, Repligen ( NASDAQ:RGEN growth stocks Not much else stood out for the business, but that shouldn't be confused with a lack of progress. Repligen made progress integrating its largest acquisition ever, C Technologies, and still managed to end September with a record $ million in cash. Considering that the company has been built on acquisitions, shareholders can't discount the possibility that another could be on the way. Here's what investors need to know about Repligen's latest operating results. Image source: Getty Images. Steady growth, steady progress Repligen reported $9. million in revenue during the third quarter of 09, marking a 0% increase from the year-ago period. While that growth was accomplished with a .7% gross margin, the company reported a % rise in research and development (R&D) and selling, general, and administration expenses. Shareholders shouldn't be alarmed. M
Show less
Read more
Impact Snapshot
Event Time:
RGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGEN alerts
High impacting Repligen Corporation news events
Weekly update
A roundup of the hottest topics
RGEN
News
- Repligen Corporation to Present at Upcoming Investor ConferencesGlobeNewswire
- Repligen to Report Third Quarter 2024 Financial ResultsGlobeNewswire
- Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release [Yahoo! Finance]Yahoo! Finance
- Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More [Yahoo! Finance]Yahoo! Finance
- Repligen Co. (NASDAQ: RGEN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $205.00 price target on the stock.MarketBeat
RGEN
Earnings
- 7/30/24 - In-Line
RGEN
Sec Filings
- 10/23/24 - Form SC
- 9/18/24 - Form 8-K
- 9/12/24 - Form 4
- RGEN's page on the SEC website